Top-News

Cascadian Therapeutics News

Aktie
WKN:  A2DHCB ISIN:  US14740B6065
Keine aktuellen Kursdaten verfügbar
Handeln Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Aktienanzahl *
21,66 Mio.
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 30.11.2016

Cascadian Therapeutics News

01.02.18 - PR Newswire
SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of Cascadian Therapeutics, Inc. - CASC
SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of Cascadian Therapeutics, Inc. - CASC PR Newswire
31.01.18 - PR Newswire
Cascadian (CASC) Alert: Johnson Fistel Investigates Proposed Sale of Cascadian Therapeutics, Inc.; Is $10.00 a Fair Price for Shareholders?
Cascadian (CASC) Alert: Johnson Fistel Investigates Proposed Sale of Cascadian Therapeutics, Inc.; Is $10.00 a Fair Price for Shareholders? PR Newswire
11.08.14 - PR Newswire
Oncothyreon Reports Second Quarter 2014 Financial Results
Oncothyreon Reports Second Quarter 2014 Financial Results PR Newswire
11.08.14 - PR Newswire
Oncothyreon Announces Acquisition of Alpine Biosciences
Oncothyreon Announces Acquisition of Alpine Biosciences PR Newswire
04.08.14 - PR Newswire
Oncothyreon Announces Second Quarter 2014 Financial Results Conference Call
Oncothyreon Announces Second Quarter 2014 Financial Results Conference Call PR Newswire
02.06.14 - PR Newswire
Oncothyreon Announces Presentation of ONT-10 Data at ASCO Annual Meeting
Oncothyreon Announces Presentation of ONT-10 Data at ASCO Annual Meeting PR Newswire
29.05.14 - PR Newswire
Oncothyreon and Celldex Therapeutics Announce Collaboration for Combination Immunotherapy Clinical Trial of ONT-10 and Varlilumab
Oncothyreon and Celldex Therapeutics Announce Collaboration for Combination Immunotherapy Clinical Trial of ONT-10 and Varlilumab PR Newswire
28.05.14 - PR Newswire
Oncothyreon to Present at Jefferies 2014 Global Healthcare Conference
Oncothyreon to Present at Jefferies 2014 Global Healthcare Conference PR Newswire
02.05.14 - PR Newswire
Oncothyreon Reports First Quarter 2014 Financial Results
Oncothyreon Reports First Quarter 2014 Financial Results PR Newswire
30.04.14 - PR Newswire
Oncothyreon Announces First Quarter 2014 Financial Results Conference Call
Oncothyreon Announces First Quarter 2014 Financial Results Conference Call PR Newswire
07.04.14 - PR Newswire
Oncothyreon Announces Merck KGaA, Darmstadt, Germany, Initiation of Phase 3 START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer
Oncothyreon Announces Merck KGaA, Darmstadt, Germany, Initiation of Phase 3 START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer PR Newswire
13.03.14 - PR Newswire
Oncothyreon Reports Full Year and Fourth Quarter 2013 Financial Results
Oncothyreon Reports Full Year and Fourth Quarter 2013 Financial Results PR Newswire
06.03.14 - PR Newswire
Oncothyreon Announces Full Year and Fourth Quarter 2013 Financial Results Conference Call
Oncothyreon Announces Full Year and Fourth Quarter 2013 Financial Results Conference Call PR Newswire
26.02.14 - PR Newswire
Oncothyreon to Present at Cowen and Company 34th Annual Health Care Conference
Oncothyreon to Present at Cowen and Company 34th Annual Health Care Conference PR Newswire
20.02.14 - PR Newswire
Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with TDM-1 in Patients with Metastatic HER2+ Breast Cancer
Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with TDM-1 in Patients with Metastatic HER2+ Breast Cancer PR Newswire
03.02.14 - PR Newswire
Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with Capecitabine and/or Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with Capecitabine and/or Trastuzumab in Patients with Metastatic HER2+ ...
12.11.13 - PR Newswire
Oncothyreon Reports Third Quarter 2013 Financial Results
Oncothyreon Reports Third Quarter 2013 Financial Results PR Newswire
08.11.13 - PR Newswire
Oncothyreon Announces Presentation of Data from Phase 1Trial of ONT-10
Oncothyreon Announces Presentation of Data from Phase 1Trial of ONT-10 PR Newswire
04.11.13 - PR Newswire
Oncothyreon Announces Third Quarter 2013 Financial Results Conference Call
Oncothyreon Announces Third Quarter 2013 Financial Results Conference Call PR Newswire
07.10.13 - PR Newswire
Oncothyreon Announces Presentation of Final Results from Phase 1 Trial of ONT-380
Oncothyreon Announces Presentation of Final Results from Phase 1 Trial of ONT-380 PR Newswire

Newssuche

Videos

newspaper
09:00 Uhr 0,00%
Technical Trading: Erdgas nach Rücksetzer Long
Erdgas Long Typ: Turbo Open End WKN: VM6KAH Hebel: 2,11 Laufzeit: OpenEnd Einstieg: Market ... Mehr »